Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abemaciclib

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

Eli Lilly HQ

UK court backs Actavis in dispute over Lilly’s Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

Eli Lilly HQ

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Hopes for approval later this year after the drug outperformed Humira in trials

Roche Basel Switzerland

Price cut keeps Kadcyla on CDF

Comes after pressure from campaign groups

Eli Lilly HQ

Lilly wins breakthrough designation for breast cancer drug

CDK 4 and 6 inhibitor Abemaciclib's development to be expedited by FDA

Roche's Perjeta pertuzumab

Roche’s Perjeta launches in UK for early breast cancer

Says nearly 2,000 women each year could benefit from its drug

Eli Lilly HQ

Third positive phase III trial for Lilly/Incyte’s baricitinib

Baricitinib beats methotrexate in rheumatoid arthritis

- PMLiVE

Pfizer starts Ibrance trials in early breast cancer

Hopes to encourage wider use of breakthrough drug

Roche's Perjeta pertuzumab

European approval for Roche’s next-gen breast cancer drug

Perjeta now available in EU for use before surgery in early stage aggressive breast cancer

- PMLiVE

NHS sponsors charity on metastatic breast cancer study

Breast Cancer Now to study tissue shortly after death

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links